denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Scientific Program
Session: JOINT SESSION: Therapeutic Gene Editing of Stem Cells in Classical and Malignant Hematology
Hematology Disease Topics & Pathways:
Sickle Cell Disease, Research, Acute Myeloid Malignancies, AML, Antibody Therapy, Translational Research, Bispecific Antibody Therapy, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Hemoglobinopathies, Diseases, Gene Therapy, Treatment Considerations, Biological therapies, Immunotherapy, Myeloid Malignancies, Monoclonal Antibody Therapy, Technology and Procedures, Gene editing, Transplantation (Allogeneic and Autologous)
Session: JOINT SESSION: Therapeutic Gene Editing of Stem Cells in Classical and Malignant Hematology
Hematology Disease Topics & Pathways:
Sickle Cell Disease, Research, Acute Myeloid Malignancies, AML, Antibody Therapy, Translational Research, Bispecific Antibody Therapy, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Hemoglobinopathies, Diseases, Gene Therapy, Treatment Considerations, Biological therapies, Immunotherapy, Myeloid Malignancies, Monoclonal Antibody Therapy, Technology and Procedures, Gene editing, Transplantation (Allogeneic and Autologous)
Sunday, December 8, 2024, 9:30 AM-11:05 AM
Disclosures: No relevant conflicts of interest to declare.